230 related articles for article (PubMed ID: 22230480)
1. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L; Marzo I; Anel A; Naval J
Biochem Pharmacol; 2012 Jun; 83(11):1475-83. PubMed ID: 22230480
[TBL] [Abstract][Full Text] [Related]
2. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
3. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
4. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
5. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
6. New insights into apoptosis signaling by Apo2L/TRAIL.
Gonzalvez F; Ashkenazi A
Oncogene; 2010 Aug; 29(34):4752-65. PubMed ID: 20531300
[TBL] [Abstract][Full Text] [Related]
7. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
9. Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL.
Holland PM
Cancer Lett; 2013 May; 332(2):156-62. PubMed ID: 21220186
[TBL] [Abstract][Full Text] [Related]
10. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
Bouralexis S; Findlay DM; Evdokiou A
Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
12. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
13. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2.
Frese S; Pirnia F; Miescher D; Krajewski S; Borner MM; Reed JC; Schmid RA
Oncogene; 2003 Aug; 22(35):5427-35. PubMed ID: 12934102
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
15. Targeting death-inducing receptors in cancer therapy.
Takeda K; Stagg J; Yagita H; Okumura K; Smyth MJ
Oncogene; 2007 May; 26(25):3745-57. PubMed ID: 17530027
[TBL] [Abstract][Full Text] [Related]
16. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
[TBL] [Abstract][Full Text] [Related]
17. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA
Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755
[TBL] [Abstract][Full Text] [Related]
18. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
19. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
20. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
